GSK takes rights to cardiovascular program from China-based SiranBio: Deals Report

With emerging clinical data showing that ALK7 knockdown is associated with reductions in visceral fat, GSK has taken most global rights to an siRNA program from China-based SiranBio addressing the target, associated with cardiovascular risk.

While the size of the deal’s upfront payment remains undisclosed,  Suzhou Siran Biotechnology Co. Ltd. said it’s eligible to receive more than $1 billion in total payments from GSK plc (LSE:GSK; NYSE:GSK) in the agreement, plus royalties. The global deal excludes rights in mainland China, Hong Kong, Macau and Taiwan, which remain with SiranBio...